Tacedinaline (Synonyms: N-acetyldinaline; CI-994; Goe-5549)

目錄號(hào): HY-50934 純度: 99.32%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Tacedinaline (N-acetyldinaline) 是組蛋白脫乙酰酶(HDAC)的抑制劑，抑制重組 HDAC 1, 2 和 3 的 IC₅₀ 值分別為 0.9，0.9，1.2 μM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Tacedinaline Chemical Structure

CAS No. : 112522-64-2

1. 客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥440	In-stock
1 mg	￥125	In-stock
5 mg	￥250	In-stock
10 mg	￥400	In-stock
50 mg	￥1200	In-stock
100 mg	￥2000	In-stock
200 mg	￥3400	In-stock
500 mg	現(xiàn)貨	詢價(jià)
1 g		詢價(jià)
5 g		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

MCE 顧客使用本產(chǎn)品發(fā)表的 6 篇科研文獻(xiàn)

•Nat Commun. 2023 Sep 22;14(1):5916. [Abstract]
•Nutrients. 2023 Jun 15, 15(12), 2760.
•Int J Mol Sci. 2022 Apr 2;23(7):3980. [Abstract]
•Front Neurosci. 2021 Oct 6;15:674745. [Abstract]
•J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
•SLAS Discov. 2022 Oct 11;S2472-5552(22)13702-0. [Abstract]

Tacedinaline 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HDAC 亞型特異性產(chǎn)品:

查看所有亞型

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

生物活性
實(shí)驗(yàn)參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC₅₀s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.

IC₅₀ & Target^[1]

HD1

0.9 μM (IC₅₀)

HD2

0.9 μM (IC₅₀)

HD3

1.2 μM (IC₅₀)

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	IC₅₀	11.29 μM Compound: CI994	Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A-375	IC₅₀	11.29 μM Compound: CI994	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
A-375	IC₅₀	11.3 μM Compound: Tacedinaline	Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay	[PMID: 30108928]
A-375	IC₅₀	9.64 μM Compound: 5; CI994	Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
A549	IC₅₀	10.17 μM Compound: 2	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
A549	IC₅₀	15.96 μM Compound: CI-994	Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	[PMID: 31223439]
A549	IC₅₀	16.45 μM Compound: 5; CI994	Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
A549	IC₅₀	20.1 μM Compound: CI994	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A549	IC₅₀	20.1 μM Compound: 6; CI994	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
A549	IC₅₀	20.1 μM Compound: Tacedinaline	Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay	[PMID: 30108928]
Epithelial cell	IC₅₀	> 50 μM Compound: 18, pfizer,CI-994	Cytotoxicity against human mammary epithelial cells by MTT assay Cytotoxicity against human mammary epithelial cells by MTT assay	[PMID: 17941625]
HCT-116	IC₅₀	10 μM Compound: 5; CI-994	Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HCT-116	IC₅₀	4 μM Compound: 18, pfizer,CI-994	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 17941625]
HCT-116	IC₅₀	6.39 μM Compound: 5; CI994	Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
HCT-116	IC₅₀	7.71 μM Compound: CI994	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HCT-116	IC₅₀	7.71 μM Compound: CI994	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HCT-116	IC₅₀	7.71 μM Compound: 6; CI994	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
HCT-116	EC₅₀	8.4 μM Compound: Cl-994	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by cell-titer glo assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by cell-titer glo assay	[PMID: 35293758]
HCT-116	IC₅₀	9.83 μM Compound: 2	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
HeLa	IC₅₀	1.81 μM Compound: 5; CI994	Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay	[PMID: 31103900]
HeLa	IC₅₀	1.81 μM Compound: CI994	Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 31003060]
HeLa	IC₅₀	13.43 μM Compound: 5; CI994	Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
HeLa	IC₅₀	18.02 μM Compound: CI994	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HeLa	IC₅₀	18.78 μM Compound: CI994	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HepG2	IC₅₀	10 μM Compound: 5; CI-994	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HepG2	IC₅₀	18.5 μM Compound: Tacedinaline	Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay	[PMID: 30108928]
HepG2	IC₅₀	18.51 μM Compound: 6; CI994	Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
LNCaP	IC₅₀	7.4 μM Compound: 3, CI-994	Antiproliferative activity against human LNCap by MTT assay Antiproliferative activity against human LNCap by MTT assay	[PMID: 18166465]
MCF7	IC₅₀	13.16 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
MDA-MB-231	GI₅₀	0.17 μM Compound: 1	Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay	[PMID: 18543902]
MGC-803	IC₅₀	11.6 μM Compound: CI994	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
MGC-803	IC₅₀	11.6 μM Compound: 6; CI994	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay	[PMID: 28391133]
NCI-H1299	IC₅₀	33.79 μM Compound: CI994	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
NCI-H1299	IC₅₀	33.8 μM Compound: Tacedinaline	Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay	[PMID: 30108928]
NCI-H1299	IC₅₀	6.79 μM Compound: 2	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
NCI-H460	IC₅₀	9.7 μM Compound: Tacedinaline	Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay	[PMID: 30108928]
NCI-H661	IC₅₀	20 μM Compound: CI-994	Antiproliferative activity against human NCI-H661 cells after 48 hrs Antiproliferative activity against human NCI-H661 cells after 48 hrs	[PMID: 18692397]
NIH3T3	IC₅₀	9.05 μM Compound: CI994	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 31003060]
NIH3T3	IC₅₀	9.05 μM Compound: 5; CI994	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
PC-3	GI₅₀	0.29 μM Compound: 1	Growth inhibition of human PC3 cells after 5 days by MTT assay Growth inhibition of human PC3 cells after 5 days by MTT assay	[PMID: 18543902]
Sf9	IC₅₀	147 nM Compound: 27; CI-994	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence ass Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence ass	[PMID: 30735902]
Sf9	IC₅₀	41 nM Compound: 27; CI-994	Inhibition of recombinant human full length C-terminal His/FALG-tagged HDAC1 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence Inhibition of recombinant human full length C-terminal His/FALG-tagged HDAC1 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence	[PMID: 30735902]
SMMC-7721	IC₅₀	> 32 μM Compound: CI994	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
SMMC-7721	IC₅₀	14.06 μM Compound: 5; CI994	Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay	[PMID: 31103900]
SMMC-7721	IC₅₀	16.9 μM Compound: Tacedinaline	Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay	[PMID: 30108928]

體外研究
(In Vitro)

Tacedinaline (N-acetyldinaline) 是一種新型口服化合物，在臨床前模型中具有廣譜抗腫瘤活性。作用機(jī)制可能涉及抑制組蛋白去乙酰化和細(xì)胞周期停滯。Tacedinaline (N-acetyldinaline) 與常用于非小細(xì)胞肺癌細(xì)胞系管理的抗腫瘤藥物聯(lián)合使用，在 Tacedinaline (N-acetyldinaline) (40 μM) 和吉西他濱 (0.01 μM) 在處理 48 和 72 小時(shí)^[2]。
Tacedinaline (N-acetyldinaline) 抑制有絲分裂原刺激的血淋巴細(xì)胞增殖，IC₅₀ 值為 3 μM^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Tacedinaline (CI-994) 可在大鼠單次口服后 1 天內(nèi)影響淋巴組織，這種影響通常在 7 天內(nèi)可逆^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

269.30

Formula

C₁₅H₁₅N₃O₂

CAS 號(hào)

112522-64-2

性狀

固體

顏色

White to gray

中文名稱

乙酰地那林；他地那蘭

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : ≥ 50 mg/mL (185.67 mM; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.7133 mL	18.5667 mL	37.1333 mL
5 mM	0.7427 mL	3.7133 mL	7.4267 mL
10 mM	0.3713 mL	1.8567 mL	3.7133 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.28 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.32%

選擇批次：

Data Sheet (637 KB) SDS (393 KB)

COA (191 KB) HNMR (122 KB) LCMS (80 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. [Content Brief]

[2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. [Content Brief]

[3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. [Content Brief]

[4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74. [Content Brief]

Animal Administration ^[4]	Rats: To characterize the effects of Tacedinaline (CI-994) on lymphoid tissue, male rats are administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. [Content Brief] [2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. [Content Brief] [3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. [Content Brief] [4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74. [Content Brief]

Animal Administration
^[4]

Rats: To characterize the effects of Tacedinaline (CI-994) on lymphoid tissue, male rats are administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

[1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. [Content Brief]

[2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. [Content Brief]

[3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. [Content Brief]

[4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74. [Content Brief]

Tacedinaline 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.7133 mL	18.5667 mL	37.1333 mL	92.8333 mL
	5 mM	0.7427 mL	3.7133 mL	7.4267 mL	18.5667 mL
	10 mM	0.3713 mL	1.8567 mL	3.7133 mL	9.2833 mL
	15 mM	0.2476 mL	1.2378 mL	2.4756 mL	6.1889 mL
	20 mM	0.1857 mL	0.9283 mL	1.8567 mL	4.6417 mL
	25 mM	0.1485 mL	0.7427 mL	1.4853 mL	3.7133 mL
	30 mM	0.1238 mL	0.6189 mL	1.2378 mL	3.0944 mL
	40 mM	0.0928 mL	0.4642 mL	0.9283 mL	2.3208 mL
	50 mM	0.0743 mL	0.3713 mL	0.7427 mL	1.8567 mL
	60 mM	0.0619 mL	0.3094 mL	0.6189 mL	1.5472 mL
	80 mM	0.0464 mL	0.2321 mL	0.4642 mL	1.1604 mL
	100 mM	0.0371 mL	0.1857 mL	0.3713 mL	0.9283 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tacedinaline112522-64-2N-acetyldinaline CI-994 Goe-5549乙酰地那林他地那蘭CI994CI 994CI-994Goe5549Goe 5549Goe-5549HDACApoptosisHistone deacetylasesInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門(mén)：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Tacedinaline (Synonyms: N-acetyldinaline; CI-994; Goe-5549)

Customer Review

MCE 顧客使用本產(chǎn)品發(fā)表的 6 篇科研文獻(xiàn)

Tacedinaline 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HDAC 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Tacedinaline 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Tacedinaline (Synonyms: N-acetyldinaline; CI-994; Goe-5549)

Customer Review

Tacedinaline 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 6 篇科研文獻(xiàn)

Tacedinaline 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HDAC 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Tacedinaline 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Tacedinaline 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z